|
Cellix Ltd showcase two new biochips at the 9th World Congress for Microcirculation |
|
September 2010, Paris, Cellix Limited showcase two new biochips; the Vena8 Fluoro+TM and the Vena8 Endothelial+TM at the 9th World Congress for Microcirculation. Cellix’s microfluidic based biochips have revolutionised drug discovery through their unique biochip designs which mimic human capillaries. The biochips allow for the precise control of microlitre volumes of biochemical samples and reagents.
The latest biochip designs, Vena8 Fluoro+TM and Vena8 Endothelial+TM biochips integrate flow based cell adhesion assays with increased optical performance using fluorescence immunostaining and confocal microscopy.
Vena8 Fluoro+TM Biochips contain 8 parallel enclosed microcapillaries for continuous flow cell based assays: cell-receptor ligand rolling, binding/adhesion assays under shear flow. Each microcapillary may be coated with a different adhesion molecule. Vena8 Fluoro+TM Biochips are particularly suited for fluorescent immunostaning or confocal microscopy combined with flow based experiments. Ideal for study of thrombosis applications: platelet adhesion, aggregation and thrombi formation.
Vena8 Endothelial+TM Biochips contain 8 parallel enclosed microcapillaries for culturing primary endothelial cells and continuous flow cell based assays. Primary endothelial cells are cultured and cell suspensions may then be injected using the MirusTM Nanopump which supports a range of shear stresses/shear flow rates for dynamic flow based assays. Vena8 Endothelial+TM Biochips enable real time imaging of cell-cell interaction, cell rolling, adhesion and migration in the biochips under conditions of physiological flow (shear stress/shear flow) for applications in different therapeutic areas. Ideal for applications in inflammation and oncology: leukocyte-endothelial (cell-cell) interactions; adhesion, migration and transmigration studies.
Cellix’s biochips enable researchers to mimic in vivo disease microenvironments allowing detailed dissection of disease processes at the cellular level where shear stress or continuous flow parameters are known to affect physiologic events.
About Cellix Ltd
Cellix Ltd. is a privately held instrumentation and cell-based assay company developing technologies that accurately mimic in vivo human blood vessels under physiological flow for cell-based screening in drug discovery. The Company is headquartered in Dublin, Ireland, and maintains offices in New York City.
|
For additional information on this release, please contact:
|
|
Marketing Department
|
|
Phone: 00 353 1 896 27 99 begin_of_the_skype_highlighting00 353 1 896 2799
|
|
Contact: Rachel Ashe, Marketing Executive
|
|
|
|
